Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-003535
Filing Date
2017-05-04
Accepted
2017-05-04 16:30:33
Documents
69
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q clvs-20170331x10q.htm 10-Q 1502751
2 EX-10.39 clvs-20170331ex1039dd6f6.htm EX-10.39 322445
3 EX-31.1 clvs-20170331ex3114163f7.htm EX-31.1 20081
4 EX-31.2 clvs-20170331ex312d11ed9.htm EX-31.2 20321
5 EX-32.1 clvs-20170331ex321b54f49.htm EX-32.1 8036
6 EX-32.2 clvs-20170331ex322af751a.htm EX-32.2 8417
  Complete submission text file 0001558370-17-003535.txt   6183521

Data Files

Seq Description Document Type Size
7 EX-101.INS clvs-20170331.xml EX-101.INS 1253366
8 EX-101.SCH clvs-20170331.xsd EX-101.SCH 40678
9 EX-101.CAL clvs-20170331_cal.xml EX-101.CAL 57808
10 EX-101.DEF clvs-20170331_def.xml EX-101.DEF 93552
11 EX-101.LAB clvs-20170331_lab.xml EX-101.LAB 413041
12 EX-101.PRE clvs-20170331_pre.xml EX-101.PRE 274838
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

EIN.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35347 | Film No.: 17814415
SIC: 2834 Pharmaceutical Preparations